Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Abraham Kocheril

Clinical Cardiac Electrophysiology Champaign, IL Medical Doctor

NPI 1639194541 CMS profile 209555

101 W University Ave, Champaign, IL 61820

Open in the dashboard

General payments

$192,091

772 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Abraham Kocheril of Champaign, IL is reported in the CMS Open Payments database as having received $192,091 across 772 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,742 98
2024 General $13,507 94
2023 General $19,957 132
2022 General $11,614 106
2021 General $14,077 95
2020 General $13,797 43
2019 General $106,397 204

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Abraham Kocheril
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Abraham Kocheril were reported at $12,742. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Abraham Kocheril Clinical Cardiac Electrophysiology median Middle half National median
2019 $106,397 $2,361 $585–$8,260 $163
2020 $13,797 $993 $247–$4,351 $114
2021 $14,077 $1,185 $326–$4,739 $132
2022 $11,614 $2,073 $554–$6,789 $149
2023 $19,957 $2,568 $759–$8,159 $160
2024 $13,507 $2,557 $703–$7,403 $164
2025 $12,742 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $32,736 47 payments
  2. Lundbeck LLC $29,102 23 payments
  3. Biosense Webster, Inc. $17,316 70 payments
  4. Kowa Pharmaceuticals America, Inc. $16,970 39 payments
  5. Abbott Laboratories $14,818 120 payments
  6. Medtronic, Inc. $11,458 92 payments
  7. Sanofi-Aventis U.S. LLC $11,343 14 payments
  8. Biotronik Inc. $9,059 87 payments
  9. CardioFocus, Inc. $7,400 43 payments
  10. Medical Device Business Services, Inc. $7,368 20 payments
  11. Other $34,520 217 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $51,812 139 payments
  2. Food and Beverage $48,178 602 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $40,388 12 payments
  4. Honoraria $36,925 13 payments
  5. Consulting Fee $14,781 5 payments
  6. Education $7 1 payment
Products named General payments · program years 2019–2025
  1. XARELTO $32,736 47 payments
  2. NORTHERA $29,102 23 payments
  3. Carto 3 System $12,218 28 payments
  4. CartoSound $10,024 9 payments
  5. Carto 3 $8,931 56 payments
  6. Carto Smarttouch $8,016 10 payments
  7. Livalo $7,344 34 payments
  8. ELIQUIS $6,853 5 payments
  9. MULTAQ $6,694 6 payments
  10. Heartlight System $5,659 29 payments
  11. Other $61,583 560 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

1,503

Median for Cardiology: 2,533

Drug cost

$506,978

Median for Cardiology: $485,213

Branded share of claims

27%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 182 $254,258
Xarelto Rivaroxaban Brand 138 $160,629
Jardiance Empagliflozin Brand 41 $45,690
Flecainide Acetate Generic 342 $17,321
Entresto Sacubitril/Valsartan Brand 15 $15,634
Amiodarone Hcl Generic 121 $2,740
Metoprolol Succinate Generic 145 $2,514
Carvedilol Generic 129 $1,799
Propafenone Hcl Generic 26 $1,619
Spironolactone Generic 70 $882

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$95,507

Medicare's payments for the services billed

Medicare patients

602

Average age 77

Services billed

1,805

247 women, 355 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 60%
Heart failure 49%
Ischemic heart disease 47%
Arthritis 42%
Diabetes 37%
Chronic kidney disease 30%
COPD 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Sotalol Hydrochloride
$600 18 —
JARDIANCE
$371 41 —
FARXIGA
$245 — —
LEQVIO
$137 — —
Livalo
$129 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

772 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record